ANEBULO PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Amortization of Debt Issuance Costs of $34.88 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $17.44K, a 70.79% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $17.44K, a 70.79% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-06-30 was $17.44K, a 70.79% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-03-31 was $245.18K, a 310.72% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2025 was $382.01K, a 152.60% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2024 was $151.23K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $17.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $34.88K 10-Q · filed 2026-02-12 | $52.32K derived: sum of 3 quarters · filed 2026-02-12 | $297.50K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-09-30 | $17.44K 10-Q · filed 2025-11-13 | $34.88K derived: sum of 2 quarters · filed 2025-11-13 | $280.06K derived: sum of 3 quarters · filed 2025-11-13 | $339.76K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | $17.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $262.62K derived: sum of 2 quarters · filed 2025-09-29 | $322.32K derived: sum of 3 quarters · filed 2026-02-12 | $382.01K 10-K · filed 2025-09-29 |
| 2025-03-31 | $245.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $304.88K derived: sum of 2 quarters · filed 2026-02-12 | $364.57K 10-Q · filed 2025-05-13 | $424.27K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $59.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $119.39K 10-Q · filed 2026-02-12 | $179.09K derived: sum of 3 quarters · filed 2026-02-12 | $238.78K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $59.70K 10-Q · filed 2025-11-13 | $119.39K derived: sum of 2 quarters · filed 2025-11-13 | $179.09K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $59.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $119.39K derived: sum of 2 quarters · filed 2025-09-29 | $151.23K 10-K · filed 2025-09-29 | |
| 2024-03-31 | $59.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $91.53K 10-Q · filed 2025-05-13 | ||
| 2023-12-31 | $31.84K 10-Q · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |